Skip to main content
OpenTrials
Completed

NCT Number: NCT01553916

Neuroprotective Effects of Lithium in Patients With Small Cell Lung Cancer Undergoing Radiation Therapy to the Brain

This phase I/II trial studies the effects and safety of giving lithium carbonate (lithium) to patients with small cell lung cancer (SCLC) undergoing radiation therapy to the brain (PCI; prophylactic cranial irradiation). PCI is used to prevent cancer metastases from returning in the brain. This treatment can cause short-term memory problems by damaging the hippocampus. Lithium may help prevent or lessen memory problems caused by PCI by protecting the hippocampus.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Small Cell Lung Carcinoma Bronchial Neoplasms Carcinoma, Bronchogenic Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Washinton University School of Medicine

St Louis, Missouri, 63110, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient must have histologically or cytologically confirmed small cell lung cancer. Patients with either limited or extensive stage disease are eligible.
  • Patient must have completed 4-6 cycles of platinum-based chemotherapy (+/- thoracic radiotherapy).
  • Patient must have no evidence of progressive disease on restaging imaging within 3 months of enrollment
  • For patients taking medications known to have a significant interaction with lithium carbonate, these medications should be discontinued at least 1 week prior to and during lithium treatment
  • Patient must be > or = 18 years old.
  • Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2
  • Leukocytes >= 3,000/mcL
  • Absolute neutrophil count >= 1,500/mcL
  • Platelets >= 100,000/mcL
  • Total bilirubin =< 1.5 x institutional upper limit of normal (IULN)
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =< 3.0 x IULN
  • Creatinine within normal institutional limits OR creatinine clearance >= 50 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
  • Patient must have an electrocardiogram without evidence of arrhythmia, QT prolongation (QTc > 450 ms in males and > 470 ms in females), or other severe dysfunction within 2 weeks of initiation of lithium
  • Women of childbearing potential (women with regular menses, women with amenorrhea, women with irregular cycles, women using a contraceptive method that precludes withdrawal bleeding, and women who have had a tubal ligation) are required to have a negative urine pregnancy test within 14 days prior to the first dose of lithium.
  • Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately
  • Patient (or legally authorized representative if applicable) must be able to understand and willing to sign an Internal Review Board (IRB) approved written informed consent document

Exclusion criteria

  • Patient must not have history of prior cranial radiotherapy
  • Patient must not have brain metastases present prior to initiation of initial therapy or PCI
  • Patient must not have evidence of progressive disease
  • Patient must not have received chemotherapy within 3 weeks of initiation of PCI
  • Patient must not have a history of other malignancy =< 2 years previous with the exception of basal cell or squamous cell carcinoma of the skin which were treated with local resection only or carcinoma in situ of the cervix
  • Patient must not be actively receiving any other investigational agents
  • Patient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to lithium carbonate
  • Patient must not have any uncontrolled intercurrent illness including, but not limited to, ongoing or active infection symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Patient must not have any uncontrolled thyroid disease
  • Patient must not have a seizure disorder
  • Patient must not be pregnant and/or breastfeeding

Treatment and study plan

Lithium Carbonate

Drug

Other names: Eskalith, Lithane, Lithium, Lithobid, Lithonate, Lithotabs

Prophylactic Cranial Irradiation

Radiation

Other names: PCI

Primary outcomes

  1. Safety of Lithium Carbonate as Measured by Number of Patients in the Safety lead-in Who Experienced a Dose-limiting Toxicity (DLT)

    Time frame: 3 weeks

    -Graded and described using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v 4. Safety will be defined as < 2 patients experiencing DLTs of the first 6 treated.

  2. Immediate Recall Memory Deterioration as Measured by the Hopkins Verbal Learning Test - Immediate Recall (HVLT-IR) Total Score

    Time frame: 3 months

    • The HVLT is a word learning test measuring episodic visual memory
    • The immediate recall memory deterioration test portion consists of 36 words split into 3 sections (animals, gemstones, places of shelter, types of birds, tools, items of clothing, kitchen utensils,weapons, and alcoholic beverages)
    • The words were read aloud and the participants was asked to freely recall them immediately. The list was read a second time followed by a second free recall trial. This was followed by a third reading and third free recall.
    • The words recalled for each trial were recorded and a total recall score tallied (range: 0-36).
    • The higher the score the better the recall

Secondary outcomes

  1. Immediate Recall Memory Deterioration as Measured by the Hopkins Verbal Learning Test - Immediate Recall (HVLT-IR) Total Score

    Time frame: 6 months

    • The HVLT is a word learning test measuring episodic visual memory
    • The immediate recall memory deterioration test portion consists of 36 words split into 3 sections (animals, gemstones, places of shelter, types of birds, tools, items of clothing, kitchen utensils,weapons, and alcoholic beverages)
    • The words were read aloud and the participants was asked to freely recall them immediately. The list was read a second time followed by a second free recall trial. This was followed by a third reading and third free recall.
    • The words recalled for each trial were recorded and a total recall score tallied (range: 0-36).
    • The higher the score the better the recall

  2. Immediate Recall Memory Deterioration as Measured by the Hopkins Verbal Learning Test - Immediate Recall (HVLT-IR) Total Score

    Time frame: 12 months

    • The HVLT is a word learning test measuring episodic visual memory
    • The immediate recall memory deterioration test portion consists of 36 words split into 3 sections (animals, gemstones, places of shelter, types of birds, tools, items of clothing, kitchen utensils,weapons, and alcoholic beverages)
    • The words were read aloud and the participants was asked to freely recall them immediately. The list was read a second time followed by a second free recall trial. This was followed by a third reading and third free recall.
    • The words recalled for each trial were recorded and a total recall score tallied (range: 0-36).
    • The higher the score the better the recall

  3. Delayed Recall Memory Deterioration as Measured by the Hopkins Verbal Learning Test - Delayed Recall (HVLT-DR) Total Score

    Time frame: 3 months

    • The HVLT is a word learning test measuring episodic visual memory
    • The delayed recall memory deterioration test portion consists of 36 words split into 3 sections (animals, gemstones, places of shelter, types of birds, tools, items of clothing, kitchen utensils,weapons, and alcoholic beverages)
    • The words were read aloud and the participants was asked to freely recall them 20-25 minutes later.
    • The words recalled were recorded and a total recall score tallied (range: 0-36).
    • The higher the score the better the recall

  4. Delayed Recall Memory Deterioration as Measured by the Hopkins Verbal Learning Test - Delayed Recall (HVLT-DR) Total Score

    Time frame: 6 months

    • The HVLT is a word learning test measuring episodic visual memory
    • The delayed recall memory deterioration test portion consists of 36 words split into 3 sections (animals, gemstones, places of shelter, types of birds, tools, items of clothing, kitchen utensils,weapons, and alcoholic beverages)
    • The words were read aloud and the participants was asked to freely recall them 20-25 minutes later.
    • The words recalled were recorded and a total recall score tallied (range: 0-36).
    • The higher the score the better the recall

  5. Delayed Recall Memory Deterioration as Measured by the Hopkins Verbal Learning Test - Delayed Recall (HVLT-DR) Total Score

    Time frame: 12 months

    • The HVLT is a word learning test measuring episodic visual memory
    • The delayed recall memory deterioration test portion consists of 36 words split into 3 sections (animals, gemstones, places of shelter, types of birds, tools, items of clothing, kitchen utensils,weapons, and alcoholic beverages)
    • The words were read aloud and the participants was asked to freely recall them 20-25 minutes later.
    • The words recalled were recorded and a total recall score tallied (range: 0-36).
    • The higher the score the better the recall

  6. Changes in Quality-of-life as Measured by Overall Quality of Life Using the EORTC QLQ30

    Time frame: 3 months

    • Assessed by comparing questionnaire test scores to baseline; European Organization for Research and Treatment of Cancer (EORTC) QLQ30 (global health/QOL, cognitive functioning, and fatigue scales)
    • 30 total questions with 28 questions having answers ranging from 1-4 with 1=not at all and 4= very much and 2 questions ranging from 0-7 with 1-very poor and 7=excellent
    • Raw scores will be transformed to a 100-point scale (0=lowest score, 100=highest score)
    • The higher the score the lower the quality of life

  7. Changes in Quality-of-life as Measured by Overall Quality of Life Using the Total Score of the EORTC QLQ-BN20

    Time frame: 12 months

    Assessed by comparing questionnaire test scores to baseline; BN20 (future uncertainty and communications deficit scales)

    • 20 questions with answers ranging from 1-4 with 1=not at all and 4=very much
    • Raw scores will be transformed to a 100-point scale (0=lowest score, 100=highest score)
    • The higher the score the lower quality of life

  8. Feasibility of Performing Serial Neurocognitive Testing and Quality of Life Exams as Measured by Number of Patients Who Complete the Neurocognitive Testing and Quality of Life Exams

    Time frame: 3 months

    -Defined as at least 4 of 6 patients successfully completing pre-treatment and 3 month post-treatment testing

  9. Change in Hippocampal Morphology Following Lithium + PCI as Measured by Total Hippocampal Volume

    Time frame: Baseline through 12 months

  10. Number of Participants With Brain Metastases

    Time frame: 12 months

    1-year rate of brain metastases

  11. Number of Central Nervous System (CNS) Adverse Events

    Time frame: Through 12 months

    Adverse events will be tabulated by type and grade using NCI CTCAE v 4.

  12. Rate of Overall Survival

    Time frame: 12 months

    -Overall survival is defined as the time between date of on study and date of death due to any cause

Sponsors and collaborators

Lead sponsor

Washington University School of Medicine

Other

Registry information

Official study title

Phase I/II Trial of Lithium as a Neuroprotective Agent for Patients With Small Cell Lung Cancer (SCLC) Treated With Prophylactic Cranial Irradiation (PCI)

Important dates

Study start
2012
Primary completion
2016
Study completion
2017
First posted
Mar 14, 2012
Registry last updated
Jul 5, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.